Stopping or Pausing Your GLP-1 — What the Studies, the Labels and Your Prescriber Each Decide

Three named studies answer the question most people are really asking, which is what happens to weight when the medication stops.

The STEP 1 trial extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022, followed 327 adults with obesity or overweight and without diabetes for a year after the trial ended. Participants had taken once-weekly semaglutide, the molecule in Novo Nordisk's Wegovy, or placebo for 68 weeks, and then stopped both the drug and the lifestyle programme. From week 0 to week 68 the semaglutide group had lost a mean 17.3 percent of body weight. By week 120, a year off treatment, they had regained 11.6 percentage points and sat 5.6 percent below where they started. The authors describe that as regaining about two-thirds of the prior loss, and report that most cardiometabolic improvements reverted towards baseline over the same year.

The Wegovy prescribing information, revised June 2026, describes a second design. In its Study 5, the trial published as STEP 4, 902 adults took Wegovy for a 20-week run-in; the 803 who reached the maintenance dose were randomized to continue or switch to placebo. From week 20 to week 68, the placebo group's weight rose by a mean 6.9 percent while the continuing group fell a further 7.9 percent. The label itself adds the caveat that because people who stopped during titration were excluded, the results may not reflect the general population starting the drug.

The Zepbound prescribing information, revised August 2026, reports the tirzepatide equivalent, SURMOUNT-4, which Aronne and colleagues published in JAMA in January 2024. Of 783 adults who started Eli Lilly's Zepbound, 670 reached randomization at week 36 with a mean loss of 20.9 percent. Over the next 52 weeks the placebo group regained a mean 14.0 percent of body weight; the group that continued tirzepatide lost a further 5.5 percent. The label notes that 17.9 percent of the placebo group and 10.4 percent of the tirzepatide group discontinued the study drug after randomization.

The hedge the evidence requires is this: every one of those numbers is a mean from a trial population that tolerated the drug, reached a maintenance dose and received structured lifestyle counselling throughout. Within the STEP 1 extension the spread was wide, and none of these studies can tell you what your own weight will do. They tell you the direction most people moved in, and that direction was up.

The labels do not contain a section called "stopping", but they say more about it than most people expect, and the wording matters because it shows who the instructions are addressed to.

The Wegovy label lists specific situations in which the prescriber discontinues the drug: if pancreatitis is suspected, if a serious hypersensitivity reaction occurs, and for patients taking it for weight reduction or cardiovascular risk reduction, when a pregnancy is recognized. The Zepbound label likewise says to discontinue when pregnancy is recognized. These are clinical decisions written for clinicians, and they are the reason a sudden new symptom is a phone call rather than a private decision to skip a week.

On pregnancy planning, the semaglutide labels are explicit. Both the Wegovy label (section 8.3) and the Ozempic label, revised May 2026, say to discontinue the drug at least two months before a planned pregnancy because of semaglutide's long half-life, and the Wegovy Medication Guide repeats that instruction to patients in plain language. The Zepbound label does not give a comparable lead time but does advise people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for a period after starting and after each dose increase, which is its own reason to involve the prescriber in family planning.

On breaks, the Wegovy label's section 2.4 is the sentence to know. It tells the prescriber that if two or more consecutive weekly doses are missed, dose escalation is reinitiated at a lower dosage to reduce the risk of gastrointestinal adverse reactions. The Zepbound label's missed-dose section addresses a single missed dose and contains no instruction for resuming after a longer break. In both cases the label hands the restart to the prescriber, which is exactly what this page will do too.

What the labels do not say is also worth stating. None of them describes a taper or a step-down for stopping, and none describes a withdrawal syndrome; the only washout language in any of them is the semaglutide labels' two-month lead time before a planned pregnancy. The consequences they document are the ones in the withdrawal studies: appetite and weight move back towards where they were.

Stopping is the majority experience rather than the exception. The largest recent estimate comes from Rodriguez and colleagues in JAMA Network Open, published in January 2025, who followed 125,474 US adults with overweight or obesity who started liraglutide, semaglutide or tirzepatide between 2018 and 2023. Within one year, 64.8 percent of those without type 2 diabetes and 46.5 percent of those with it had discontinued. Among the 41,792 people who stopped and had weight data available for the reinitiation analysis, 36.3 percent of those without diabetes and 47.3 percent of those with it had restarted within a year. Gastrointestinal adverse events raised the likelihood of stopping, and each additional percentage point of weight regained raised the likelihood of restarting.

Side effects are the reason the labels quantify. The Zepbound label reports that across its two pooled weight-reduction trials, 4.8 to 6.7 percent of tirzepatide participants permanently discontinued because of adverse reactions, against 3.4 percent on placebo, mostly gastrointestinal and mostly in the first months. The Wegovy label reports permanent discontinuation for a gastrointestinal adverse reaction in 4.3 percent of adults on the injection versus 0.7 percent on placebo. If nausea, vomiting or abdominal pain is why you are thinking of stopping, that is a symptom to report, not just a decision to make, because the labels also list persistent severe abdominal pain among the signs that need urgent evaluation.

Cost and coverage are the reasons the labels do not measure but the cohort data implies. Coverage changes at renewal, prior authorizations expire, and savings offers end. None of that is a clinical reason to stop, which is precisely why it deserves a conversation with the prescriber and pharmacist before the last pen runs out. The GLP-1 cost and savings guide covers the routes that exist without quoting prices.

Supply was a documented reason for involuntary pauses. The FDA listed both molecules in shortage for years and formally declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Local gaps still happen, and a pharmacy that cannot fill a prescription is a reason to call the prescriber the same day rather than to stretch a pen.

Pregnancy planning is the one reason with a label timetable attached, as described above, and it is a conversation to have well before you intend to conceive rather than after.

This is the point where a scenario page has to refuse to be helpful in the way some readers want. We will not say where a restart begins, and the reason is in the label text quoted above: the Wegovy label instructs the prescriber to reinitiate escalation after a gap of two or more consecutive doses because resuming a maintenance dose after a break raises the risk of gastrointestinal reactions. That is a decision that depends on the product, how long you were away, how far along you were when you stopped, why you stopped and what has changed since. A website does not know any of those things; your prescriber can ask.

Three things make that conversation short. First, the dates: when the last dose was taken and how many weeks the pause has run. Second, the reason, stated plainly, because a pause for cost is a different conversation from a pause for vomiting. Third, what happened during the pause, which is where a record earns its place. Weight over the break, appetite, any symptoms that resolved or appeared, and any other medications started or stopped.

If you stopped because of side effects, say which ones and when they eased. The Rodriguez cohort found that moderate or severe gastrointestinal events made people less likely to restart at all, and a prescriber who knows what happened last time can plan around it rather than repeat it.

The practical side of picking the record back up, including what to do about the gap in your log, lives in how to restart GLP-1 tracking after a gap. Read that once the prescriber has made the clinical call, not instead of it.

A pause is the one period where people stop tracking, and it is the period whose data the restart conversation most needs. Keep four things going.

Weight, on the same scale at the same time of day, at whatever frequency you can sustain. The withdrawal studies say weight tends to rise after stopping; your own trend line says whether and how fast it is happening to you, which is what your prescriber will want to see. Read it as a trend rather than as single mornings, and use the GLP-1 weight loss plateau guide to tell a flat stretch from a genuine reversal.

Meals, at least roughly, with protein first. Appetite typically returns as the drug clears, and a log that shows when meals grew and where protein went is more useful than a memory of "eating more".

Symptoms, with dates. If nausea, reflux or fatigue was why you stopped, the date it resolved after the last dose is a data point your prescriber does not otherwise have. If a new symptom appears during the pause, it is worth a call regardless of the medication.

The last dose, clearly marked. Log the final dose with its date and note that the medication is paused. GLP-1 Tracker is free on iPhone, and keeps doses, weight, meals and notes in one on-device record with the last dose marked. Its medication-level view will simply show the estimate falling towards zero after the last logged dose; that curve is an educational illustration built from your log, not a measurement, and it must not be used to decide when to restart.

Most pauses are not emergencies, and the ones that are, such as a suspected pancreatitis or a recognized pregnancy, are already handled by the label's instruction to contact the prescriber. For everything else, the best moment to talk about stopping is before the last dose rather than after.

Ask the prescriber what they expect over the pause and what would make them want to hear from you sooner. Ask the pharmacist whether any other medication you take was adjusted because of the GLP-1, since the labels for insulin and sulfonylurea users note that doses of those drugs are sometimes reduced when a GLP-1 is added, and a pause may change that picture. Ask both of them what a restart would look like in principle, so the later call is a confirmation rather than a first discussion.

If cost is the driver, ask about coverage appeals and manufacturer programmes before stopping, because those processes take weeks and a documented plan is easier to defend than a lapsed one. If supply is the driver, ask which pharmacies the prescriber can send the prescription to and how quickly.

Then keep the record. The trial data on this page describe what happened to groups of people who stopped inside a study. Your own log is the only source that describes what happened to you, and it is the thing that turns "I stopped for a while" into a conversation your prescriber can act on.